Research

Pipeline

  • StaphTAME

    GangaGen´s lead product is, StaphTAME, a proprietary recombinant protein, P128, for the prevention or treatment of Staphylococcal infections, including infection with methicillin-resistant Staphylococcus aureus (MRSA).

    P128

  • Clinical

    Nasal decolonization of S.aureus – first in human study of P128 (StaphTAME)

    Clinical

  • Phage Therapy

    In addition to treating bacterial diseases, bacteriophage preparations can be used as prophylactics to control or prevent epidemics.

    Bacteriophage Therapy.

  • Products in the pipeline

    Tuberculosis

    Gram negative infections

    Phages that kill without release of bacterial toxic contents

    C.difficile

    E.coli.